Quantification of anidulafungin and micafungin in human body fluids by high performance-liquid chromatography with UV-detection.
Anidulafungin
/ analysis
Ascitic Fluid
/ chemistry
Candidiasis, Invasive
/ drug therapy
Chromatography, High Pressure Liquid
/ methods
Drug Monitoring
/ methods
Humans
Limit of Detection
Linear Models
Micafungin
/ analysis
Reproducibility of Results
Solid Phase Extraction
Spectrophotometry, Ultraviolet
/ methods
Antifungals
Candidiasis
Echinocandins
Invasive fungal infection
Solid phase extraction
Therapeutic drug monitoring
Journal
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554
Informations de publication
Date de publication:
15 Feb 2020
15 Feb 2020
Historique:
received:
16
09
2019
revised:
03
12
2019
accepted:
10
12
2019
pubmed:
21
1
2020
medline:
21
4
2020
entrez:
21
1
2020
Statut:
ppublish
Résumé
The echinocandins anidulafungin (ANID) and micafungin (MICA) are recommended for treatment of invasive Candida infections. As target-site concentrations of antimicrobial agents are crucial for eradication of pathogens, we established and validated high-performance liquid chromatography-UV detection (HPLC-UV) assays for quantification of ANID and MICA in human plasma, ascites fluid, pleural effusion, and in cerebrospinal fluid (CSF). Sample pre-purification was performed by protein precipitation with acetonitrile followed by solid phase extraction. For both assays, intra- and interday precision, and accuracy fulfilled the requirements for bioanalytical methods issued by the European Medicine Agency (EMA). The lower limit of quantification was 0.01 mg/L for both drugs. At 25 °C, ANID and MICA concentrations declined by up to 70% within 24 h. Concentrations remained stable over 24 h at 4 °C and over four weeks at -80 °C. In conclusion, the developed methods are fit for the assessment of target-site pharmacokinetics of ANID and MICA in clinical studies.
Identifiants
pubmed: 31958565
pii: S1570-0232(19)31391-1
doi: 10.1016/j.jchromb.2019.121937
pii:
doi:
Substances chimiques
Anidulafungin
9HLM53094I
Micafungin
R10H71BSWG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121937Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 565
Pays : Austria
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest R.B. has received an IIR grant from Pfizer, has received honoraria from Basiliea and Merck Sharp & Dohme, and he is a member of an advisory board of Merck Sharp & Dohme. All other authors have no conflict of interest to declare.